VanEck Associates
TAK icon

VanEck Associates’s Takeda Pharmaceutical TAK Stock Holding History

VanEck Associates’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8M Sell
1,674,005
-586,099
-26% -$9.7M 0.02% 399
2026
Q1 		$41.9M Sell
2,260,104
-45,293
-2% -$795K 0.03% 298
2025
Q4 		$35.9M Buy
2,305,397
+1,143,117
+98% +$16.3M 0.03% 289
2025
Q3 		$17M Sell
1,162,280
-169,152
-13% -$2.51M 0.02% 396
2025
Q2 		$20.6M Sell
1,331,432
-840,952
-39% -$12.4M 0.02% 337
2025
Q1 		$32.3M Sell
2,172,384
-38,044
-2% -$533K 0.04% 248
2024
Q4 		$29.3M Buy
2,210,428
+35,192
+2% +$483K 0.04% 255
2024
Q3 		$30.1M Buy
2,175,236
+134,407
+7% +$1.91M 0.04% 243
2024
Q2 		$26.4M Buy
2,040,829
+356,069
+21% +$4.71M 0.04% 239
2024
Q1 		$23.4M Buy
1,684,760
+360,844
+27% +$5.25M 0.04% 242
2023
Q4 		$18.9M Buy
1,323,916
+45,616
+4% +$647K 0.03% 259
2023
Q3 		$19.8M Buy
1,278,300
+226,754
+22% +$3.51M 0.04% 242
2023
Q2 		$16.5M Buy
1,051,546
+34,691
+3% +$568K 0.04% 275
2023
Q1 		$16.8M Sell
1,016,855
-768,351
-43% -$12.2M 0.04% 266
2022
Q4 		$27.8M Sell
1,785,206
-76,816
-4% -$1.07M 0.07% 204
2022
Q3 		$24.1M Sell
1,862,022
-127,750
-6% -$1.78M 0.07% 200
2022
Q2 		$27.9M Buy
1,989,772
+862,502
+77% +$12.3M 0.07% 209
2022
Q1 		$16.1M Sell
1,127,270
-26,806
-2% -$394K 0.03% 287
2021
Q4 		$15.7M Buy
1,154,076
+281,425
+32% +$3.95M 0.04% 289
2021
Q3 		$14.3M Buy
872,651
+249,686
+40% +$4.19M 0.04% 296
2021
Q2 		$10.5M Buy
622,965
+60,231
+11% +$1.03M 0.02% 342
2021
Q1 		$10.3M Sell
562,734
-44,044
-7% -$792K 0.03% 338
2020
Q4 		$11M Buy
606,778
+18,080
+3% +$317K 0.03% 289
2020
Q3 		$10.5M Buy
588,698
+27,839
+5% +$507K 0.03% 255
2020
Q2 		$10.1M Buy
560,859
+72,748
+15% +$1.31M 0.04% 257
2020
Q1 		$7.41M Buy
488,111
+44,999
+10% +$816K 0.04% 261
2019
Q4 		$8.74M Buy
443,112
+70,140
+19% +$1.34M 0.03% 280
2019
Q3 		$6.42M Sell
372,972
-66,367
-15% -$1.15M 0.03% 294
2019
Q2 		$7.78M Buy
439,339
+30,751
+8% +$560K 0.04% 262
2019
Q1 		$8.32M Buy
+408,588
New +$8.22M 0.04% 244

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

VanEck Associates's TAK Position: Q2 2026 in Review

VanEck Associates reduced its Takeda Pharmaceutical (TAK) stake by 26% in Q2 2026, selling an estimated $9.7M and leaving 1,674,005 shares worth $26.8M. The position accounts for 0.02% of the portfolio, ranked #399.

VanEck Associates first reported a position in TAK in Q1 2019 and has held it in 30 quarters since. The position peaked at $41.9M in Q1 2026. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • VanEck Associates held 1,674,005 shares of Takeda Pharmaceutical worth $26.8M as of Q2 2026.
  • VanEck Associates sold 586,099 Takeda Pharmaceutical shares in Q2 2026, an estimated $9.7M.
  • Takeda Pharmaceutical made up 0.02% of VanEck Associates's portfolio in Q2 2026, its #399 holding.
  • VanEck Associates first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 30 quarters since.
  • VanEck Associates's Takeda Pharmaceutical position peaked at $41.9M in Q1 2026.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.